Physician profile
Mitchell Davis
NPI 1841878634
$82,407.69
in general payments reported to CMS, 2019-2025
14 companies · $1,835 in 2025
The $1,835 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41K · 2023: $39K · 2024: $572 · 2025: $1,835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $39K · Food and Beverage: $2,238 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $38,629.42 |
| Food and Beverage | $2,237.71 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80,000.00 | 2022-2023 | |
| Genzyme Corporation | $942.55 | 2024-2025 | |
| Abbvie INC. | $333.79 | 2024-2025 | |
| Ucb, INC. | $312.02 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $221.53 | 2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $107.88 | 2025 | Zoryve |
| Kerecis Limited | $100.29 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Janssen Biotech, INC. | $89.99 | 2025 | Tremfya |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Amgen INC. | $79.80 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $72.52 | 2025 | Opzelura |
| Leo Pharma INC. | $27.30 | 2025 | Anzupgo |
| Galderma Laboratories, L.P. | $21.12 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $18.91 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.